128 related articles for article (PubMed ID: 8270986)
1. Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
Hartmann LC; Podratz KC; Keeney GL; Kamel NA; Edmonson JH; Grill JP; Su JQ; Katzmann JA; Roche PC
J Clin Oncol; 1994 Jan; 12(1):64-9. PubMed ID: 8270986
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of p53 accumulation in epithelial ovarian carcinomas.
Berker B; Dunder I; Ensari A; Cengiz SD
Arch Gynecol Obstet; 2002 Aug; 266(4):205-9. PubMed ID: 12192480
[TBL] [Abstract][Full Text] [Related]
3. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
[TBL] [Abstract][Full Text] [Related]
5. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma.
Klemi PJ; Pylkkänen L; Kiilholma P; Kurvinen K; Joensuu H
Cancer; 1995 Oct; 76(7):1201-8. PubMed ID: 8630898
[TBL] [Abstract][Full Text] [Related]
6. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
[TBL] [Abstract][Full Text] [Related]
7. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer.
Anttila M; Kosma VM; Ji H; Wei-Ling X; Puolakka J; Juhola M; Saarikoski S; Syrjänen K
J Clin Oncol; 1998 Aug; 16(8):2591-600. PubMed ID: 9704708
[TBL] [Abstract][Full Text] [Related]
9. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
10. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer.
Anttila MA; Ji H; Juhola MT; Saarikoski SV; Syrjänen KJ
Int J Gynecol Pathol; 1999 Jan; 18(1):42-51. PubMed ID: 9891240
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53 expression in ovarian granulosa cell tumors.
Ala-Fossi SL; Mäenpää J; Aine R; Koivisto P; Koivisto AM; Punnonen R
Gynecol Oncol; 1997 Sep; 66(3):475-9. PubMed ID: 9299263
[TBL] [Abstract][Full Text] [Related]
13. Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance.
Suzuki M; Ohwada M; Saga Y; Kohno T; Takei Y; Sato I
Oncology; 2001; 60(2):170-5. PubMed ID: 11244333
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary.
Werness BA; Freedman AN; Piver MS; Romero-Gutierrez M; Petrow E
Gynecol Oncol; 1999 Dec; 75(3):413-8. PubMed ID: 10600299
[TBL] [Abstract][Full Text] [Related]
15. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer.
Ikeda K; Sakai K; Yamamoto R; Hareyama H; Tsumura N; Watari H; Shimizu M; Minakami H; Sakuragi N
Int J Gynecol Cancer; 2003; 13(6):776-84. PubMed ID: 14675314
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
19. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
20. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
